Loading organizations...
§ Private Profile · Zwijnaarde, Oost-Vlaanderen, Belgium
Biotechnology single-domain antibody therapies for viral infections, focused on respiratory viruses and immunocompromised patients.
ExeVir Bio is a Ghent, Belgium-based biotechnology company that develops single-domain antibody therapies derived from llamas to target viral respiratory infections. The clinical-stage firm utilizes a modular platform to engineer multi-specific antibodies with extended half-lives, focusing on providing broad protection for immunocompromised and elderly patients against diseases like COVID-19 and influenza. The organization recently advanced its lead COVID-19 antibody candidate, XVR013m, through Phase 1a and 1b clinical trials. To support its research and clinical pipeline, the enterprise has secured €42 million in Series A venture capital financing alongside €18 million in non-dilutive European grant funding. ExeVir Bio is backed by a syndicate of prominent institutional investors that includes Fund+, UCB Ventures, V-Bio Ventures, and SRIW. The company was founded in 2020 by professors Nico Callewaert and Xavier Saelens.
ExeVir Bio has raised $105.5M across 4 funding rounds.
ExeVir Bio has raised $105.5M in total across 4 funding rounds.
ExeVir Bio has raised $105.5M across 4 funding rounds. Most recently, it raised $1.8M Grant in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 28, 2023 | $1.8M Grant | Vlaio | — | Announced |
| Jan 9, 2023 | $26.7M Debt Financing | Kris Peeters | — | Announced |
| May 24, 2021 | $50M Series A | Philippe Monteyne | Belgian Family Offices, Noshaq, Sambrinvest, Stef Heylen, MD, Caroline Thielen, Erica Whittaker, Katja Rosenkranz, Jerome VAN Biervliet, Joël Henneghien | Announced |
| Jul 28, 2020 | $27M Venture Round | Philippe Monteyne | Sfpi Fpim, Erica Whittaker, Katja Rosenkranz, Jerome VAN Biervliet | Announced |
ExeVir Bio has raised $105.5M in total across 4 funding rounds.
ExeVir Bio's investors include VLAIO, Kris Peeters, Philippe Monteyne, Belgian family offices, Noshaq, Sambrinvest, Stef HEYLEN, MD, Caroline THIELEN, Erica Whittaker, Katja Rosenkranz, Jerome Van Biervliet, Joël Henneghien.